{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1&page=8",
    "query": {
      "intervention": "Part 1",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 6229,
    "total_pages": 623,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T06:22:13.111Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06974786",
      "title": "Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma, Newly Diagnosed",
        "Multiple Myeloma (MM)"
      ],
      "interventions": [
        {
          "name": "Elranatamab",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "autologous stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-08-08",
      "completion_date": "2033-04",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-11-11T06:22:13.111Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06974786"
    },
    {
      "nct_id": "NCT02138383",
      "title": "Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2014-05-22",
      "completion_date": "2019-10-07",
      "has_results": false,
      "last_update_posted_date": "2021-08-17",
      "last_synced_at": "2026-11-11T06:22:13.111Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02138383"
    },
    {
      "nct_id": "NCT02473354",
      "title": "Predictors of Opioid-Induced Respiratory Depression (OIRD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Depression"
      ],
      "interventions": [
        {
          "name": "Remifentanil",
          "type": "DRUG"
        },
        {
          "name": "Oxygen",
          "type": "DRUG"
        },
        {
          "name": "Carbon dioxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 30,
      "start_date": "2015-04",
      "completion_date": "2018-04-29",
      "has_results": false,
      "last_update_posted_date": "2020-03-10",
      "last_synced_at": "2026-11-11T06:22:13.111Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02473354"
    },
    {
      "nct_id": "NCT01934205",
      "title": "To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections, Bacterial"
      ],
      "interventions": [
        {
          "name": "GSK2140944 (Single dose)",
          "type": "DRUG"
        },
        {
          "name": "GSK2140944 (Multiple dose)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 22,
      "start_date": "2013-09-25",
      "completion_date": "2013-12-21",
      "has_results": false,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-11-11T06:22:13.111Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01934205"
    },
    {
      "nct_id": "NCT02980341",
      "title": "Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Patritumab Deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2016-11-28",
      "completion_date": "2023-09-07",
      "has_results": true,
      "last_update_posted_date": "2024-10-30",
      "last_synced_at": "2026-11-11T06:22:13.111Z",
      "location_count": 10,
      "location_summary": "Newnan, Georgia • Chicago, Illinois • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Newnan",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02980341"
    },
    {
      "nct_id": "NCT01501383",
      "title": "A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "VX-765 Part A",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "VX-765 Part B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 55,
      "start_date": "2011-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-09-30",
      "last_synced_at": "2026-11-11T06:22:13.111Z",
      "location_count": 22,
      "location_summary": "Northport, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 18 more",
      "locations": [
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01501383"
    },
    {
      "nct_id": "NCT04113551",
      "title": "A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Attention Deficit Disorder With Hyperactivity"
      ],
      "interventions": [
        {
          "name": "MPH (Concerta)",
          "type": "DRUG"
        },
        {
          "name": "MPH (Ritalin)",
          "type": "DRUG"
        },
        {
          "name": "Atomoxetine (ATO)",
          "type": "DRUG"
        },
        {
          "name": "Guanfacine (GFC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 17418,
      "start_date": "2019-10-01",
      "completion_date": "2020-01-10",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-11-11T06:22:13.111Z",
      "location_count": 1,
      "location_summary": "Titusville, New Jersey",
      "locations": [
        {
          "city": "Titusville",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04113551"
    },
    {
      "nct_id": "NCT03727451",
      "title": "A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Hypertension",
        "Pulmonary Fibrosis",
        "Sarcoidosis, Pulmonary"
      ],
      "interventions": [
        {
          "name": "iNO",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Bellerophon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 17,
      "start_date": "2019-01-30",
      "completion_date": "2022-06-15",
      "has_results": false,
      "last_update_posted_date": "2022-08-10",
      "last_synced_at": "2026-11-11T06:22:13.111Z",
      "location_count": 6,
      "location_summary": "Miami, Florida • Cincinnati, Ohio • Philadelphia, Pennsylvania + 3 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Falls Church",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03727451"
    },
    {
      "nct_id": "NCT04649151",
      "title": "A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.222",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Years to 18 Years"
      },
      "enrollment_count": 4328,
      "start_date": "2020-12-09",
      "completion_date": "2024-06-14",
      "has_results": true,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-11-11T06:22:13.111Z",
      "location_count": 48,
      "location_summary": "Banning, California • La Mesa, California • Lake Worth, Florida + 41 more",
      "locations": [
        {
          "city": "Banning",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Lake Worth",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chamblee",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04649151"
    },
    {
      "nct_id": "NCT02765477",
      "title": "Paced Electrocardiogram Requiring Fast Emergent Coronary Therapy (PERFECT) Study",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Myocardial Infarction"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Hennepin County Medical Center, Minneapolis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1500,
      "start_date": "2016-06",
      "completion_date": "2017-07",
      "has_results": false,
      "last_update_posted_date": "2016-12-01",
      "last_synced_at": "2026-11-11T06:22:13.111Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02765477"
    }
  ]
}